Related Industry Reports:
- The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
- HIV: A Strategic Analysis of Therapeutic and Testing Markets
- HIV: Markets for Diagnostics and Therapeutics
- What's Next in Vaccines? HIV, Malaria, Rabies, MRSA, and Other Vaccine Targets in the 2010-2020 Pipeline
- AIDS and HIV INFECTION - Therapy Area Pipeline Report
Interleukin-17 regulates visceral obesity in HIV-1-infected patients.
HIV medicine 2012 Mar 30; In press
Zizza A, Guido M, Grima P
Institute of Clinical Physiology, National Research Council, Lecce, Italy.
OBJECTIVE: The aim of the study was to evaluate the interleukin-17 (IL-17) plasma level in HIV-1-infected patients and its relation to central obesity. METHODS: Eighty-four HIV-1-infected patients [42 with visceral obesity (group A) and 42 without visceral obesity (group B)] and 46 HIV-negative subjects [23 with visceral obesity (group C) and 23 without visceral obesity (group D)] were enrolled in the study. Sonographic measurements of perirenal fat diameter/body mass index (PRFD/BMI) were used to assess visceral adipose tissue thickness. RESULTS: HIV-1-infected patients had higher plasma levels of IL-17 than HIV-negative subjects [837.8 ± 260 pg/mL (mean ± standard deviation) vs. 395.3 ± 138.6 pg/mL, respectively; P < 0.001]. Furthermore, HIV-1-infected patients with a diagnosis of visceral obesity had lower levels of IL-17 than HIV-infected lean patients (756.9 ± 282.9 pg/mL vs. 918.7 ± 208.4 pg/mL, respectively; P < 0.01). IL-17 (r = -0.21; P = 0.03) and waist circumference (r = 0.48; P < 0.001) were significantly associated with visceral adipose tissue thickness. A negative correlation of IL-17 (r = -0.23; P < 0.001) with PRFD/BMI was found. CONCLUSIONS: This study suggests a linear negative association between IL-17 and visceral adipose tissue thickness.